Filing Details

Accession Number:
0001179110-20-008883
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-11 16:40:46
Reporting Period:
2020-08-07
Accepted Time:
2020-08-11 16:40:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA Biological Products, (No Disgnostic Substances) (2836) 043561634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1755174 Ann Jo Beltramello C/O Momenta Pharmaceuticals, Inc.
301 Binney St,
Cambridge MA 02142
Chief Hr And Inf. Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Commonstock Acquisiton 2020-08-07 2,690 $18.85 59,796 No 4 M Direct
Common Stock Acquisiton 2020-08-07 1,346 $0.00 61,142 No 4 M Direct
Common Stock Disposition 2020-08-07 2,690 $32.00 58,452 No 4 S Direct
Common Stock Disposition 2020-08-10 622 $32.36 57,830 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-08-07 1,326 $0.00 1,326 $18.85
Common Stock Stock Option (Right to Buy) Disposition 2020-08-07 1,364 $0.00 1,364 $18.85
Common Stock Restricted Stock Units Disposition 2020-08-07 1,346 $0.00 1,346 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,888 2019-05-07 2027-02-07 No 4 M Direct
21,400 2018-02-07 2027-02-07 No 4 M Direct
2,691 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  2. Shares received pursuant to settlement of Restricted Stock Units that were granted on February 7, 2017.
  3. Restricted Stock Units convert into common stock on a one-for-one basis.
  4. Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years.